The Chemours Company (CC) Proxy Filing summary

Executive summary

• Refreshed business strategy, Pathway to Thrive, launched in 2024 with four pillars: Operational Excellence, Enabling Growth, Portfolio Management, and Strengthening the Long Term.

• New CEO Denise Dignam and CFO Shane Hostetter appointed in 2024, strengthening leadership.

• 2024 financial results: Net sales of $5.8B (down 5%), net income $86M, adjusted EBITDA $786M (down 22%).

• Significant progress in cost savings, especially in Titanium Technologies (TT) with $140M saved in 2024.

• Achieved 52% reduction in Scope 1 and 2 GHG emissions since 2018, advancing toward 2030 goals.

Voting matters and shareholder proposals

• Election of 12 director nominees for one-year terms.

• Advisory vote on executive compensation (say-on-pay).

• Ratification of PricewaterhouseCoopers LLP as independent auditor for 2025.

• Proposal to eliminate supermajority voting provisions for amendments to certificate and bylaws.

• Shareholder proposal to require biodiversity impact assessments before mining in sensitive areas; Board recommends against.

Board of directors and corporate governance

• Board refreshment: new independent directors added in 2024 and 2025, bringing expertise in finance, technology, legal, and sustainability.

• 11 of 12 director nominees are independent; Board Chair is independent.

• Committees: Audit, Compensation and Leadership Development (CLDC), Nominating and Corporate Governance (NCG), and Environmental, Health, and Safety & Operational Performance (EHS&O).

• Annual board and committee self-evaluations, director peer assessments, and ongoing director education.

• Enhanced Code of Conduct and new Speak-Up Policy implemented in 2024.